Thomas Fuller | SOPA Photographs | Lightrocket | Getty Photographs
UniQure must run one other research to show that its gene remedy “truly helps individuals with Huntington’s illness,” a senior U.S. Meals and Drug Administration official mentioned on a name with reporters Thursday.
The official, who requested anonymity earlier than discussing delicate info, confirmed the company has requested the corporate to run a placebo managed trial of its therapy, which is run instantly into the mind. UniQure has mentioned that sort of research is not moral as a result of it might require placing individuals below common anesthesia for hours, a characterization the official disputed.
“So what is de facto happening? UniQure is the newest firm to make a failed remedy for Huntington’s sufferers,” the official mentioned. “They possible acknowledge or perceive at some deep degree that their trial failed years in the past, and as a substitute of doing the best factor and operating the proper medical research, UniQure is performing a distorted or manipulated comparability within the thoughts of FDA.”
The feedback mark the newest improvement in a messy public spat between UniQure and the FDA, and as the company comes below fireplace for a lot of latest drug approval software rejections, together with some the place firms have accused it of going again on earlier steerage. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Fast final week seemingly criticized UniQure’s gene remedy for Huntington’s illness. Makary did not identify UniQure however described its therapy.
UniQure then accused the FDA of reversing its stance that the corporate’s medical trial information could be ample to hunt approval. UniQure’s research used an out of doors database to measure how sufferers with Huntington’s illness would possibly decline with out therapy, referred to as an exterior management. UniQure has mentioned it would not be possible to run a real randomized, double-blind placebo-controlled research, thought-about the gold customary, as a result of it would not be moral to make individuals endure a sham hours-long mind surgical procedure.
The FDA official mentioned the company “by no means agreed to simply accept this distorted comparability” and the FDA “by no means makes such assurances.” As a substitute, the “FDA will at all times say, ‘Nicely, we’ve got to see the information after we get it.'”
UniQure did not instantly remark.
The corporate’s inventory rose greater than 10% on Thursday and has fallen 58% this 12 months as of Thursday afternoon.
